OBJECTIVE: To review the use of valproic acid in HIV-positive patients.
DATA SOURCES: Clinical literature was accessed through a MEDLINE search (Ja
nuary 1966-November 1998). Key search terms included HIV, AIDS, seizures, v
alproic acid, and glutathione.
DATA SYNTHESIS: Patients with HIV often develop neurologic manifestations;
therefore, valproic acid may be considered in the management of this popula
tion. It has been demonstrated that valproate may increase viral burden by
potentiating replication. An evaluation of studies addressing the use of va
lproic acid in HIV-positive patients was conducted.
CONCLUSIONS: The potential for valproate-induced increases in viral replica
tion exists. Although further studies are warranted, clinicians should exer
cise caution when using valproate in HIV-positive patients.